Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$11.23 USD
-0.36 (-3.11%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $11.22 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Liquidia Technologies, Inc. [LQDA]
Reports for Purchase
Showing records 21 - 40 ( 130 total )
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Litigation Updates, Potential Launch Timeline Remains Intact; Q1:23 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Yutrepia Progress and Interpreting Near-Term Litigation Scenarios; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Lost in the Ongoing Patent Litigation Labyrinth; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Litigation Considerations and Differentiating Yutrepia; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Reminder: How stellar is STELLAR? Review of Ph3 sotatercept data @ ACC
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: How stellar is STELLAR? Review of Ph3 sotatercept data at ACC
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Litigation Overhang Continues; Tyvaso DPI Off to Strong Start
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Path Forward for Yutrepia-Positive Steps to Litigation Resolution
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Reading the Fine PRINT; Assuming Coverage at UNDERPERFORM & $3 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Split Hatch-Waxman Decision Sparks Litigation Stalmate; D/g to UNDERPERFORM
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Hatch-Waxman Litigation Decision Now In Hand-Next Steps For Yutrepia
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A